NATICK, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the European Society of Cardiology Congress 2008, which runs from August 30 to September 3 in Munich, Germany.

The Company plans to announce 12-month data from the SYNTAX trial, which compares percutaneous coronary intervention (PCI) using the TAXUS® Express2™ Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery in the most complex patient groups.

"SYNTAX is a landmark study that will provide the medical community the first and only critical data from a randomized clinical trial related to complex patients with left main and three vessel disease treated with drug- eluting stents (DES)," said Keith D. Dawkins, M.D., Senior Vice President and Associate Chief Medical Officer at Boston Scientific. "The patients recruited in SYNTAX have exceptionally complex anatomy and advanced disease. This unique population would typically be treated with CABG and represents the most challenging group ever studied in a DES trial. SYNTAX will expand the body of knowledge of PCI use and help inform physicians as to appropriate treatment options for the sickest patients."

  Details of the Company's activities at ESC 2008 are below.

  Schedule of events (all times are Munich time)

  Monday, September 1

-- SYNTAX Study data. One-year outcomes data from the SYNTAX trial will be presented by Patrick W. Serruys, M.D., Ph.D., and Friedrich W. Mohr, M.D., Ph.D., beginning at 11:18 a.m. in the Munich Room (Zone A4). The Company plans to issue a press release at this time. SYNTAX is the first randomized, controlled clinical trial comparing PCI using drug-eluting stents to CABG in patients with left main and/or three vessel disease. The presentation will be part of an Interventional Cardiology Hot Line Session from 11:00 a.m. to 12:30 p.m., chaired by William Wijns, M.D., and Petr Widimsky, M.D.

Tuesday, September 2

-- OLYMPIA Phases II and III data. One-year results from Phases II and III of the global OLYMPIA registry will be presented by Oscar Mendiz, M.D., at 12:15 p.m., in the Copenhagen Room (Zone B3). OLYMPIA is the world's largest prospective, multi-center, multi-phased registry for a single drug-eluting stent. The registry is designed to analyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS® Liberte® Paclitaxel-Eluting Stent System. Results from more than 22,000 patients will focus on safety and efficacy, and will highlight outcomes within this high-risk patient population. The Company plans to issue a press release at this time.

-- Cardiac Rhythm Management Workshop. From 12:45-1:30 p.m., the Company will sponsor a workshop session entitled "The continuing fight against sudden death; patient selection and latest treatment enhancements," chaired by Guenter Breithardt, M.D., in the Bucharest Room (Zone A4). The workshop will include presentations from Silvia G. Priori, M.D., on "Simplifying guideline-based patient selection," and by Michael Glikson, M.D., on "Improving patient benefits with new device technology."

-- Interventional Cardiology Symposium. From 2:00-3:30 p.m., the Company will sponsor a satellite symposium entitled "Treatment algorithms in complex patients -- What do the data support?" chaired by Keith D. Dawkins, M.D., and Marie-Claude Morice, M.D., in the Bucharest Room. The symposium will explore treatment options for multi-vessel disease and left main disease with particular focus on insights gained from the SYNTAX trial data.

Boston Scientific will present its latest innovations at booth B401 in Exhibition Hall B2.

The safety and effectiveness of the TAXUS Express Stent has not been established in patients with left main or three vessel disease. In the U.S., the TAXUS Liberte Stent is an investigational device and is not available for sale.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

  CONTACT:  Paul Donovan
            508-650-8541 (office)
            508-667-5165 (mobile)
            Media Relations

            Larry Neumann
            508-650-8696 (office)
            Investor Relations
            Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Media Relations, Paul Donovan, +1-508-650-8541 (office), or
+1-508-667-5165 (mobile); or Investor Relations, Larry Neumann,
+1-508-650-8696, both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/